

FY10 Q1: Non-GAAP Reconciliations

Non-GAAP gross profit margin (in millions)	QTR 1 FY10	Gross Profit Margin
Net sales	\$ 3,933	75.4%
Cost of products sold	(966)	
Gross profit	2,967	
Restructuring charges impact Diabetes infusion set recall impact	7 16	
Gross profit, adjusted	\$ 2,990	76.0%

Income Tax Rate	QTR 1 FY10
Effective tax rate	20.7%
Tax impact of restructuring and certain litigation charges	(0.4)
Impact of foreign R&D tax credit	0.7
Non-GAAP nominal tax rate	21.0%

CardioVascular revenue constant currency growth, adjusted (in millions)	FY10 QTR 1	FY09 QTR 1	% Change
Cardiovascular revenue, as reported	\$ 689	\$ 631	9%
Currency Impact	37	-	15%
Cardiovascular revenue, at comparable currency rates	\$ 726	\$ 631	
Revenue reversal as a result of the purchase of a distributor	18	-	
Cardiovascular revenue, adjusted, at comparable currency rates	\$ 744	\$ 631	